No Data
Sichuan Shuangma: Report for the third quarter of 2024
Sichuan Hexie Shuangma (000935.SZ) released its performance for the first three quarters, with a net income of 0.245 billion yuan, a year-on-year decrease of 63.41%.
sichuan hexie shuangma (000935.SZ) released the third quarter report for 2024. In the first three quarters, the company achieved revenue...
Express News | Three mergers in a single day! The merger and reorganization market remains active, showing four major new trends.
Sichuan Hexie Shuangma (000935.SZ): Buyback completed, cumulatively spent 88.2522 million yuan to repurchase 6.2199 million shares.
On October 23, Guilonghui reported that sichuan hexie shuangma (000935.SZ) announced that as of October 22, 2024, the company's share buyback plan has been fully implemented. The actual repurchase range of the company's shares in this buyback is from November 1, 2023 to July 30, 2024. As of now, the company has repurchased a total of 6.219875 million shares through the repurchase special securities account by means of centralized bidding trading, accounting for 0.81% of the company's total share capital. The highest fill price is 17.81 yuan per share, the lowest fill price is 11.37 yuan per share, and the total trading amount is RMB 88.2522 million.
Sichuan Hexie Shuangma (000935): Acquiring assets to expand into the biomedical sector, bullish for performance growth.
Introduction to this report: The company acquires the peptide active pharmaceutical ingredient enterprise Shenzhen Jianyuan, this acquisition is beneficial for the company to seize the growth opportunities of the biomedical industry and enhance the company's profitability. Investment highlights: Maintain a 'shareholding' rating, maintain a target price of 23.7.
IDG partner Lin Dongliang is involved in the acquisition case of Sichuan Hexie Shuangma, investing nearly 1.6 billion yuan to acquire the controlling rights of Shenzhen Jianyuan.
Former "demon stock" once again crosses over into biomedical.
No Data
No Data